Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
$0.20
$0.17
$2.96
$13M-25.98N/AN/A
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
$1.35
+9.8%
$1.44
$0.65
$17.00
$22.97M1.19268,600 shs2.12 million shs
CTYX
Curative Biotechnology
$0.01
-22.2%
$0.01
$0.00
$0.22
$2.99M-33.993.01 million shs145,000 shs
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
$7.18
+3.8%
$7.45
$2.12
$12.55
$13.50M0.5329,525 shs9,275 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
0.00%0.00%0.00%0.00%-60.96%
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
0.00%+1.50%-20.12%+92.03%-90.96%
CTYX
Curative Biotechnology
-22.38%-24.51%-20.29%-48.32%-46.53%
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
0.00%-11.36%-14.52%+5.90%+717,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/AN/AN/AN/AN/AN/A
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
2.587 of 5 stars
3.34.00.00.01.10.81.3
CTYX
Curative Biotechnology
N/AN/AN/AN/AN/AN/AN/AN/A
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
1.3022 of 5 stars
3.50.00.00.00.60.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
0.00
N/AN/AN/A
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
2.50
Moderate Buy$53.003,825.93% Upside
CTYX
Curative Biotechnology
0.00
N/AN/AN/A
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
3.00
Buy$21.00192.48% Upside

Current Analyst Ratings Breakdown

Latest CTYX, NEUP, CTXR, and CHHE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2025
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00
6/30/2025
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00
6/9/2025
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
$110K0.00N/A47.17N/ANaN
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
N/AN/AN/AN/A$3.97 per shareN/A
CTYX
Curative Biotechnology
N/AN/AN/AN/AN/AN/A
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
$10K1,349.84N/AN/A$15.85 per share0.45
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
-$410K-$0.020.00N/AN/AN/AN/AN/AN/A
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
-$39.14MN/A0.001.08N/AN/A-60.03%-33.83%N/A
CTYX
Curative Biotechnology
N/AN/A0.00N/AN/AN/AN/AN/A
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
-$15.49MN/A0.00N/AN/AN/AN/AN/A9/29/2025 (Estimated)

Latest CTYX, NEUP, CTXR, and CHHE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q3 2025
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
-$0.76-$0.80-$0.04-$0.80$1.92 million$1.92 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/AN/AN/A
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
N/AN/AN/AN/AN/A
CTYX
Curative Biotechnology
N/AN/AN/AN/AN/A
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/A
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
N/A
0.47
0.14
CTYX
Curative Biotechnology
N/AN/AN/A
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
N/A
11.01
11.01
CompanyEmployeesShares OutstandingFree FloatOptionable
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
4064.95 million44.62 millionNot Optionable
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
2017.01 million15.19 millionOptionable
CTYX
Curative Biotechnology
4388.50 millionN/ANot Optionable
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
N/A1.88 million1.87 millionN/A

New MarketBeat Followers Over Time

Media Sentiment Over Time

China Health Industries stock logo

China Health Industries OTCMKTS:CHHE

China Health Industries Holdings, Inc., through its subsidiaries, manufactures and sells health products. The company operates through three segments: Humankind, HLJ Huimeijia, and Others. The company offers hemp derivative products, such as hemp oil, hemp protein powder, hemp polypeptides, collagen peptides, hemp essence repair lotions, hemp revitalizing essence products, hemp anti-aging brightening eye creams, hemp frozen age nourishing creams, hemp seed beers, and hemp seeds. It also provides health supplements, including Sailuozhi soft capsule, which is made from frog oil, soybean isoflavone, procyanidine, and vitamin E for freckle removal and skin moisture supplements under the QunLe brand; and propolis and black ant capsule that is made from propolis, black ant, acanthopanax, and astragalus root under the Kindlink brand. In addition, the company offers health products for acne removal, relieving eyestrain, enhancing bone density, enhancing memory, enhancing nutritional anemia and chloasma, relaxing bowels and promoting the discharge of lead, enhancing immunity and relieving physical fatigue, and dispelling chloasma, as well as iron and multivitamin, and mineral supplements. Further, it manufactures and sells various types of medical drugs, such as enema glycerini, umguentumacidi borici camphoratum, ge hong beriberi water, pelvic inflammation suppository, injury and paralysis tincture, indometacin and furazolidone suppositories, injury and rheumatism relieving paste, refining goupi cream, muskiness pain relieving paste, muskiness bone strengthener paste, matrine suppositories, ethacriding lactate solution, iodine tincture, mercurochrome solution, hydrogen peroxide solution, halcinonide cream, compound fluocinonide tincture, and policresulen vaginal suppository. The company primarily sells its products through sales personnel and sales agents. China Health Industries Holdings, Inc. was founded in 1996 and is based in Harbin City, the People's Republic of China.

Citius Pharmaceuticals stock logo

Citius Pharmaceuticals NASDAQ:CTXR

$1.35 +0.12 (+9.76%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$1.35 0.00 (0.00%)
As of 08/22/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Curative Biotechnology OTCMKTS:CTYX

$0.0077 0.00 (-22.22%)
As of 08/22/2025

Curative Biotechnology, Inc. engages in the provision of software solutions for the healthcare market. Its products include MedFlash, electronic Personal Health Manager, Medical Alert, personal emergency response services, product and medical transcription, disease management, revenue cycle management, and medical consulting-billing. The company was founded by Jon Pevzner on July 29, 1995 and is headquartered in Boca Raton, FL.

Neuphoria Therapeutics stock logo

Neuphoria Therapeutics NASDAQ:NEUP

$7.18 +0.26 (+3.76%)
As of 08/22/2025 04:00 PM Eastern

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.